The trial involved just nine patients, but scientists said that if
the results could be replicated in larger studies, the naturally
occurring 'reovirus' could be developed into an effective
immunotherapy for people with aggressive brain tumors.
"This is the first time it has been shown that a therapeutic virus
is able to pass through the brain-blood barrier," said Adel Samson,
a medical oncologist at the University of Leeds' Institute of Cancer
and Pathology who co-led the work.
He said their trial had shown not only that a virus could be
delivered to a tumor deep in the brain, but that when it reached its
target, "it stimulated the body's own immune defenses to attack the
cancer".

Published in the journal Science Translational Medicine on
Wednesday, the trial involved nine patients with tumors that had
either spread to the brain from other areas or were fast-growing
gliomas, an aggressive type of brain cancer.
All the patients were due to have their tumors removed surgically,
but in the days beforehand they were each given a single dose of the
reovirus administered via intravenous drip into the bloodstream.
Once the tumors were removed, the scientists analyzed samples to see
if the virus had been able to reach the cancer, which in some cases
was deep within the brain.
In all nine patients, there was evidence that the virus had reached
its target, they said. There were also signs that the replicating
virus had stimulated the immune system, with white blood cells or
so-called "killer" T-cells being drawn to the tumor to attack it.

[to top of second column] |

Because the virus only infects cancer cells and leaves healthy cells
alone, patients who received the experimental treatment reported
only mild side-effects such as slight flu-like symptoms.
Until these positive results, scientists had been doubtful about
whether the virus would be able to pass into the brain because of
the protective blood-brain barrier membrane.
However, injecting the virus directly into the brain would be
difficult and potentially dangerous.
Alan Melcher of Britain's Institute of Cancer Research, who also
co-led the study, said the results pointed a way forward for more
trials using this virus, including testing whether it can harness
the immune system to super-charge the effect of existing
chemotherapy and radiotherapy treatments.
"Now we know we can get reovirus across the blood-brain barrier, we
have begun clinical studies to see just how effective this viral
immunotherapy can be," he said.
(Reporting by Kate Kelland; Editing by Gareth Jones)
[© 2018 Thomson Reuters. All rights
reserved.] Copyright 2018 Reuters. All rights reserved. This material may not be published,
broadcast, rewritten or redistributed.
 |